Angiogenesis as a therapeutic target in breast cancer

Author(s): Angelos K. Koutras, Ioannis Starakis, Dionysia Lymperatou, Haralabos P. Kalofonos

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 12 , Issue 12 , 2012

Become EABM
Become Reviewer
Call for Editor


Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.

Keywords: Angiogenesis, bevacizumab, breast cancer, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 04 September, 2012
Page: [1230 - 1238]
Pages: 9
DOI: 10.2174/138955712802761988
Price: $65

Article Metrics

PDF: 15